Curanex Pharmaceuticals Inc operates as a developmental stage pharmaceutical company. The Company focuses on discovering, developing, and commercializing botanical drugs to treat patients suffering from immune and inflammatory diseases. Curanex Pharmaceuticals serves customers worldwide.
IPO planned for August 26, 2025, offering approximately 3.75 million shares in the price range of $4.00 to $6.00, potentially raising around $18.75 million. The company's lead drug candidate is Phyto-N, a proprietary botanical extract with anti-inflammatory properties. Curanex is focused on treating inflammatory and immune diseases and plans to list on the Nasdaq.
Key IPO Details
Company: Curanex Pharmaceuticals Inc.
Ticker Symbol: CURX
Estimated IPO Date: August 26, 2025
IPO Price Range: $4.00 - $6.00 per share
Shares Offered: 3,750,000
Deal Size (Estimated): $18.75 million
Exchange: Nasdaq
Underwriter: Pacific Century Securities
